prostate cancer

FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs
BioPharma Dive
Thu, 06/1/23 - 11:53 am
AstraZeneca
Merck
Lynparza
prostate cancer
FDA
This Startup Just Raised $90M To Fight Cancer
Crunchbase
Thu, 05/4/23 - 09:15 am
Convergent Therapeutics
funding
oncology
radiopharmaceuticals
prostate cancer
Pfizer, Astellas' Xtandi combo cuts risk of death by 58% in prostate cancer patients
Seeking Alpha
Mon, 05/1/23 - 10:13 am
Pfizer
Astellas
Xtandi
prostate cancer
clinical trials
Immunic punts psoriasis, prostate cancer programs to narrow focus onto multiple sclerosis, celiac disease
Fierce Biotech
Thu, 04/6/23 - 10:01 am
Immunic
prostate cancer
psoriasis
MS
multiple sclerosis
celiac disease
US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi
Fierce Pharma
Wed, 03/22/23 - 11:19 am
Pfizer
Astellas
Xtandi
prostate cancer
drug pricing
NIH
march-in rights
Pfizer and Astellas report positive data from prostate cancer therapy trial
Clinical Trials Arena
Fri, 03/17/23 - 10:02 am
Pfizer
Astellas
prostate cancer
clinical trials
Enzalutamide
leuprolide
Novartis takes step toward expanding supply of in-demand cancer drug
Biopharma Dive
Sun, 03/5/23 - 03:09 pm
Novartis
Pluvicto
prostate cancer
AstraZeneca, Merck's Lynparza to face FDA panel in prostate cancer bid as PARP scrutiny escalates
Fierce Pharma
Thu, 03/2/23 - 11:02 pm
AstraZeneca
Merck
Lynparza
FDA
prostate cancer
Merck reports two Phase 3 study misses for Keytruda
BioPharma Dive
Tue, 02/28/23 - 10:43 pm
Merck
clinical trials
Keytruda
prostate cancer
lung cancer
J&J wins EU backing for PARP combo Akeega in prostate cancer—but only in some patients
Fierce Pharma
Sun, 02/26/23 - 10:14 pm
JNJ
Akeega
prostate cancer
PARP inhibitors
ASCO GU: Pfizer touts Talzenna's strong showing in PARP prostate cancer battle with AstraZeneca, J&J
Fierce Pharma
Fri, 02/17/23 - 09:36 am
ASCO GU
Pfizer
Astellas
Xtandi
prostate cancer
After several flops, Merck exec stands by aggressive Keytruda prostate cancer program
Fierce Biotech
Thu, 02/16/23 - 11:06 am
Merck
Keytruda
prostate cancer
Roche Abandons AKT Prostate Cancer Asset
BioSpace
Thu, 02/2/23 - 10:52 am
Roche
AKT inhibitors
Ipatasertib
clinical trials
castration-resistant prostate cancer
prostate cancer
A Hit and a Miss for Merck’s Keytruda
BioSpace
Wed, 01/25/23 - 10:42 am
Merck
Keytruda
prostate cancer
biliary tract cancer
AstraZeneca, Merck go multilingual for prostate cancer push
Medical Marketing and Media
Mon, 01/23/23 - 09:54 pm
AstraZeneca
Merck
pharma marketing
prostate cancer
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
Fierce Biotech
Wed, 01/11/23 - 11:00 am
BioXcel Therapeutics
clinical trials
Keytruda
BXCL701
prostate cancer
Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug
Stat
Wed, 01/11/23 - 10:51 am
cancer
oncology
Joe Biden
Astellas
Xtandi
prostate cancer
JPM23: Bayer hikes sales targets for Kerendia, Nubeqa to $3B each
Fierce Pharma
Tue, 01/10/23 - 06:35 pm
Bayer
JPMHC 2023
Kerendia
prostate cancer
Nubeqa
AstraZeneca, Merck's Lynparza wins EU nod in advanced prostate cancer right after FDA delay
Fierce Pharma
Wed, 12/21/22 - 12:40 pm
AstraZeneca
Merck
Lynparza
Europe
prostate cancer
advanced prostate cancer
In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise
BioSpace
Mon, 12/5/22 - 10:58 am
Novartis
prostate cancer
Pluvicto
clinical trials
patents
patent cliff

Pages